diazoxide has been researched along with Leanness in 4 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously reported that attenuation of hyperinsulinemia by diazoxide (DZ), an inhibitor of glucose-mediated insulin secretion, increased insulin sensitivity and reduced body weight in obese Zucker rats." | 3.70 | Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. ( Alemzadeh, R; Koontz, J; Moustaid-Moussa, N; Standridge, M; Zemel, M, 2000) |
| "Chronic attenuation of hyperinsulinemia by diazoxide (DZ), an inhibitor of glucose-mediated insulin secretion, improved insulin sensitivity and glucose tolerance and caused down-regulation of lipid metabolizing enzymes in adipose tissue and decreased the rate of weight gain in mildly hyperglycemic obese Zucker rats." | 1.31 | Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats. ( Alemzadeh, R; Holshouser, S; Koontz, J; Massey, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baillargeon, JP | 1 |
| Carpentier, A | 1 |
| Kassi, EN | 1 |
| Diamanti-Kandarakis, E | 1 |
| Papavassiliou, AG | 1 |
| Standridge, M | 1 |
| Alemzadeh, R | 2 |
| Zemel, M | 1 |
| Koontz, J | 2 |
| Moustaid-Moussa, N | 1 |
| Holshouser, S | 1 |
| Massey, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for diazoxide and Leanness
| Article | Year |
|---|---|
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.
Topics: Adolescent; Adult; Androgens; Androstenedione; Diazoxide; Female; Humans; Insulin; Leuprolide; Lutei | 2007 |
Correlates between hyperinsulinism and hyperandrogenemia?
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Adenosine Triphosphate; Aldo-Keto | 2008 |
Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Diazoxide; Fatty Acid S | 2000 |
Chronic suppression of insulin by diazoxide alters the activities of key enzymes regulating hepatic gluconeogenesis in Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Diazoxide; Eating; Female; Glucokinase; Gluconeogenesis; Glucos | 2002 |